FDA Approves Inhaled Insulin (Afrezza) for Children with Diabetes
Key Questions
What did the FDA approve for children with diabetes?
The FDA approved Afrezza, an inhaled insulin, for children aged 6 and older with type 1 or type 2 diabetes. It is the first needle-free mealtime insulin option in over a century.
What did the INHALE-1 trial show about Afrezza?
The trial found Afrezza provided noninferior HbA1c control with higher treatment satisfaction. Pulmonary safety data were also reassuring.
How could this approval affect pediatric diabetes care?
It may reduce injection burden for children and improve adherence to mealtime insulin. This represents a significant advance in needle-free options.
FDA approved Afrezza for children aged 6+ with type 1 and type 2 diabetes, the first needle-free mealtime insulin option in over a century. INHALE-1 trial showed noninferior HbA1c control and higher treatment satisfaction, with reassuring pulmonary safety. This could significantly reduce injection burden and improve adherence in pediatric populations.